Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide

Roman Perez-Soler, Nouri Neamati, Yiyu Zou, Erasmus Schneider, L. Austin Doyle, Michael Andreeff, Waldemar Priebe, Yi He Ling

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Annamycin (Ann) is a highly lipophilic anthracycline antibiotic that has been shown to circumvent MDR-I both in vitro and in vivo. A liposomal formulation of Ann is currently in phase 1 clinical trials. The multidrug resistance-associated protein (MRP) has been found to be over-expressed in some human leukemias at relapse and to be a poor prognostic factor in neuroblastoma. We studied the in vitro cytotoxicity and the cellular uptake and efflux of Ann and doxorubicin (Dox) in 2 pairs of human cell lines, breast carcinoma MCF7 and small-cell lung cancer UMCC-1, and their MRP-expressing counterparts, MCF-7/VP and UMCC-I/VP. Resistance indexes were 1.1 and 1,4 for Ann vs. 6.9 and 11.6 for Dox. Ann cellular accumulation was 3- to 5-fold higher than that of Dox in both sensitive and resistant cells. No changes in drug efflux between sensitive and resistant cells were observed in the case of Ann, while Dox efflux at 1 hr was 20-25% higher in resistant than in sensitive cells. By confocal microscopy, the subcellular distribution of Ann was identical in sensitive and resistant cells, localizing mostly in the perinuclear structures, while that of Dox was exclusively nuclear in sensitive cells and nuclear and in the cell membrane in resistant cells. There was a good correlation between the extent of DNA breaks induced by each drug in the different cell lines and cytotoxic effect. Our results indicate that Ann may be effective in the treatment of malignancies in which MRP is a relevant mechanism of clinical resistance.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalInternational Journal of Cancer
Volume71
Issue number1
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Multidrug Resistance-Associated Proteins
MCF-7 Cells
Etoposide
Breast
Cell Line
Lung
Doxorubicin
Neoplasms
Viral Structural Proteins
Clinical Trials, Phase I
DNA Breaks
annamycin
Anthracyclines
Small Cell Lung Carcinoma
Neuroblastoma
Confocal Microscopy
Pharmaceutical Preparations
Leukemia
Cell Membrane
Breast Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. / Perez-Soler, Roman; Neamati, Nouri; Zou, Yiyu; Schneider, Erasmus; Doyle, L. Austin; Andreeff, Michael; Priebe, Waldemar; Ling, Yi He.

In: International Journal of Cancer, Vol. 71, No. 1, 1997, p. 35-41.

Research output: Contribution to journalArticle

@article{1e659f5cabf34e33a7f16860ca1da3a6,
title = "Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide",
abstract = "Annamycin (Ann) is a highly lipophilic anthracycline antibiotic that has been shown to circumvent MDR-I both in vitro and in vivo. A liposomal formulation of Ann is currently in phase 1 clinical trials. The multidrug resistance-associated protein (MRP) has been found to be over-expressed in some human leukemias at relapse and to be a poor prognostic factor in neuroblastoma. We studied the in vitro cytotoxicity and the cellular uptake and efflux of Ann and doxorubicin (Dox) in 2 pairs of human cell lines, breast carcinoma MCF7 and small-cell lung cancer UMCC-1, and their MRP-expressing counterparts, MCF-7/VP and UMCC-I/VP. Resistance indexes were 1.1 and 1,4 for Ann vs. 6.9 and 11.6 for Dox. Ann cellular accumulation was 3- to 5-fold higher than that of Dox in both sensitive and resistant cells. No changes in drug efflux between sensitive and resistant cells were observed in the case of Ann, while Dox efflux at 1 hr was 20-25{\%} higher in resistant than in sensitive cells. By confocal microscopy, the subcellular distribution of Ann was identical in sensitive and resistant cells, localizing mostly in the perinuclear structures, while that of Dox was exclusively nuclear in sensitive cells and nuclear and in the cell membrane in resistant cells. There was a good correlation between the extent of DNA breaks induced by each drug in the different cell lines and cytotoxic effect. Our results indicate that Ann may be effective in the treatment of malignancies in which MRP is a relevant mechanism of clinical resistance.",
author = "Roman Perez-Soler and Nouri Neamati and Yiyu Zou and Erasmus Schneider and Doyle, {L. Austin} and Michael Andreeff and Waldemar Priebe and Ling, {Yi He}",
year = "1997",
doi = "10.1002/(SICI)1097-0215(19970328)71:1<35::AID-IJC8>3.0.CO;2-4",
language = "English (US)",
volume = "71",
pages = "35--41",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide

AU - Perez-Soler, Roman

AU - Neamati, Nouri

AU - Zou, Yiyu

AU - Schneider, Erasmus

AU - Doyle, L. Austin

AU - Andreeff, Michael

AU - Priebe, Waldemar

AU - Ling, Yi He

PY - 1997

Y1 - 1997

N2 - Annamycin (Ann) is a highly lipophilic anthracycline antibiotic that has been shown to circumvent MDR-I both in vitro and in vivo. A liposomal formulation of Ann is currently in phase 1 clinical trials. The multidrug resistance-associated protein (MRP) has been found to be over-expressed in some human leukemias at relapse and to be a poor prognostic factor in neuroblastoma. We studied the in vitro cytotoxicity and the cellular uptake and efflux of Ann and doxorubicin (Dox) in 2 pairs of human cell lines, breast carcinoma MCF7 and small-cell lung cancer UMCC-1, and their MRP-expressing counterparts, MCF-7/VP and UMCC-I/VP. Resistance indexes were 1.1 and 1,4 for Ann vs. 6.9 and 11.6 for Dox. Ann cellular accumulation was 3- to 5-fold higher than that of Dox in both sensitive and resistant cells. No changes in drug efflux between sensitive and resistant cells were observed in the case of Ann, while Dox efflux at 1 hr was 20-25% higher in resistant than in sensitive cells. By confocal microscopy, the subcellular distribution of Ann was identical in sensitive and resistant cells, localizing mostly in the perinuclear structures, while that of Dox was exclusively nuclear in sensitive cells and nuclear and in the cell membrane in resistant cells. There was a good correlation between the extent of DNA breaks induced by each drug in the different cell lines and cytotoxic effect. Our results indicate that Ann may be effective in the treatment of malignancies in which MRP is a relevant mechanism of clinical resistance.

AB - Annamycin (Ann) is a highly lipophilic anthracycline antibiotic that has been shown to circumvent MDR-I both in vitro and in vivo. A liposomal formulation of Ann is currently in phase 1 clinical trials. The multidrug resistance-associated protein (MRP) has been found to be over-expressed in some human leukemias at relapse and to be a poor prognostic factor in neuroblastoma. We studied the in vitro cytotoxicity and the cellular uptake and efflux of Ann and doxorubicin (Dox) in 2 pairs of human cell lines, breast carcinoma MCF7 and small-cell lung cancer UMCC-1, and their MRP-expressing counterparts, MCF-7/VP and UMCC-I/VP. Resistance indexes were 1.1 and 1,4 for Ann vs. 6.9 and 11.6 for Dox. Ann cellular accumulation was 3- to 5-fold higher than that of Dox in both sensitive and resistant cells. No changes in drug efflux between sensitive and resistant cells were observed in the case of Ann, while Dox efflux at 1 hr was 20-25% higher in resistant than in sensitive cells. By confocal microscopy, the subcellular distribution of Ann was identical in sensitive and resistant cells, localizing mostly in the perinuclear structures, while that of Dox was exclusively nuclear in sensitive cells and nuclear and in the cell membrane in resistant cells. There was a good correlation between the extent of DNA breaks induced by each drug in the different cell lines and cytotoxic effect. Our results indicate that Ann may be effective in the treatment of malignancies in which MRP is a relevant mechanism of clinical resistance.

UR - http://www.scopus.com/inward/record.url?scp=0030887296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030887296&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19970328)71:1<35::AID-IJC8>3.0.CO;2-4

DO - 10.1002/(SICI)1097-0215(19970328)71:1<35::AID-IJC8>3.0.CO;2-4

M3 - Article

VL - 71

SP - 35

EP - 41

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -